Verona Pharma’s Phase 2 Trial Evaluating RPL554 for COPD Set to Begin
A Phase 2 clinical trial is enrolling participants to evaluate the safety and efficacy of Verona Pharma’s dry powder inhaler RPL554 as a potential maintenance treatment for people with moderate to severe chronic obstructive pulmonary disease (COPD). RPL554 is a dual inhibitor of the proteins phosphodiesterase (PDE) 3 and…